Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

Similar articles for PubMed (Select 23701654)

1.

Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients.

Dhingra R, Sharma T, Singh S, Sharma S, Tomar P, Malhotra M, Bhardwaj TR.

Mini Rev Med Chem. 2013 Aug;13(10):1475-86. Review.

PMID:
23701654
2.

A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer.

Greasley R, Khabazhaitajer M, Rosario DJ.

Cancer Manag Res. 2015 Jun 12;7:153-64. doi: 10.2147/CMAR.S50585. eCollection 2015. Review.

3.

Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.

Hoare D, Skinner TA, Black A, Robert Siemens D.

Can Urol Assoc J. 2015 Mar-Apr;9(3-4):122-7. doi: 10.5489/cuaj.2545.

4.

Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).

Penning TM.

J Steroid Biochem Mol Biol. 2015 May 29. pii: S0960-0760(15)00142-9. doi: 10.1016/j.jsbmb.2015.05.010. [Epub ahead of print]

PMID:
26032458
5.

Enzalutamide for patients with metastatic castration-resistant prostate cancer.

Ramadan WH, Kabbara WK, Al Basiouni Al Masri HS.

Onco Targets Ther. 2015 Apr 17;8:871-6. doi: 10.2147/OTT.S80488. eCollection 2015. Review.

6.

Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?

Albiges L, Loriot Y, Massard C, Fizazi K.

Eur Urol. 2015 Apr 24. pii: S0302-2838(15)00321-8. doi: 10.1016/j.eururo.2015.04.019. [Epub ahead of print] No abstract available.

PMID:
25922192
7.

[Effect and adverse event of enzalutamide and abiraterone in prostate cancer].

Kosaka T, Oya M.

Nihon Rinsho. 2015 Feb;73 Suppl 2:308-12. Japanese. No abstract available.

PMID:
25831773
8.

Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.

Schalken J, Fitzpatrick JM.

BJU Int. 2015 Mar 27. doi: 10.1111/bju.13123. [Epub ahead of print]

PMID:
25818596
9.

Anti-androgen enzalutamide enhances prostate cancer neuroendocrine (NE) differentiation via altering the infiltrated mast cells → androgen receptor (AR) → miRNA32 signals.

Dang Q, Li L, Xie H, He D, Chen J, Song W, Chang LS, Chang HC, Yeh S, Chang C.

Mol Oncol. 2015 Mar 5. pii: S1574-7891(15)00046-0. doi: 10.1016/j.molonc.2015.02.010. [Epub ahead of print]

PMID:
25817444
10.

From bench to bedside: bipolar androgen therapy in a pilot clinical study.

Zhang Q, Gray PJ.

Asian J Androl. 2015 Mar 27. doi: 10.4103/1008-682X.151390. [Epub ahead of print]

11.

PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy.

Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW.

Cancer Res. 2015 May 15;75(10):1944-8. doi: 10.1158/0008-5472.CAN-14-3602. Epub 2015 Mar 25.

PMID:
25808865
12.

Re: AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Anand AU, Bjartell A.

Eur Urol. 2015 Feb;67(2):349-50. doi: 10.1016/j.eururo.2014.11.020. No abstract available.

PMID:
25760252
13.

Does degree of androgen suppression matter in hormone-sensitive prostate cancer?

Suzman DL, Antonarakis ES.

J Clin Oncol. 2015 Apr 1;33(10):1098-100. doi: 10.1200/JCO.2014.60.1419. Epub 2015 Mar 2. No abstract available.

PMID:
25732171
14.

Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.

Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S, Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LW, Attard G.

Br J Cancer. 2015 Mar 31;112(7):1166-74. doi: 10.1038/bjc.2015.63.

PMID:
25719830
15.

Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.

Keating GM.

Drugs Aging. 2015 Mar;32(3):243-9. doi: 10.1007/s40266-015-0248-y.

PMID:
25711765
16.

Prostate cancer: Breaking AKR1C3-mediated enzalutamide resistance by inhibiting androgen synthesis.

Thoma C.

Nat Rev Urol. 2015 Mar;12(3):124. doi: 10.1038/nrurol.2015.31. Epub 2015 Feb 24. No abstract available.

PMID:
25708577
17.

Long-term Safety and Antitumor Activity in the Phase 1-2 Study of Enzalutamide in Pre- and Post-docetaxel Castration-Resistant Prostate Cancer.

Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D, Scher HI.

Eur Urol. 2015 Feb 16. pii: S0302-2838(15)00069-X. doi: 10.1016/j.eururo.2015.01.026. [Epub ahead of print]

PMID:
25698064
18.

Are androgen receptor variants a substitute for the full-length receptor?

Lu J, Van der Steen T, Tindall DJ.

Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10. Review.

PMID:
25666893
19.

Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.

Quintela ML, Mateos LL, Estévez SV, Calvo OF, Herranz UA, Afonso FJ, Santomé L, Aparicio LA.

Cancer Treat Rev. 2015 Mar;41(3):247-53. doi: 10.1016/j.ctrv.2014.12.006. Epub 2015 Jan 8. Review.

PMID:
25638257
20.

Prostate cancer: BAT-ting CRPC.

Thoma C.

Nat Rev Urol. 2015 Mar;12(3):121. doi: 10.1038/nrurol.2015.6. Epub 2015 Jan 27. No abstract available.

PMID:
25624145
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk